C4 Therapeutics Shares Are Trading Lower. The Company Announced the Abstract Sharing Clinical Data From Its Ongoing Phase 1 Clinical Trial of CFT1946 in Mutant BRAF V600 Solid Tumors, Was Released in Conjunction With the ESMO Congress 2024.
C4 Therapeutics Shares Are Trading Lower. The Company Announced the Abstract Sharing Clinical Data From Its Ongoing Phase 1 Clinical Trial of CFT1946 in Mutant BRAF V600 Solid Tumors, Was Released in Conjunction With the ESMO Congress 2024.
c4 therapeutics股票交易下跌。公司宣佈了與ESMO國際腫瘤學大會2024年同時發佈的CFT1946突變BRAF V600實體腫瘤的1期臨床試驗的概要，分享了其正在進行的臨床數據。
C4 Therapeutics Shares Are Trading Lower. The Company Announced the Abstract Sharing Clinical Data From Its Ongoing Phase 1 Clinical Trial of CFT1946 in Mutant BRAF V600 Solid Tumors, Was Released in Conjunction With the ESMO Congress 2024.
C4 Therapeutics的股價走低。該公司宣佈了與2024年ESMO大會同時發佈的共享其正在進行的針對突變BRAF V600實體瘤的 CFT1946 1期臨床試驗的臨床數據的摘要。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。